Conditionnement : 1mLx10mM(inDMSO)
Téléphone : +1 850 650 7790
Synonyms: Dehydrocortisone
| Description | Prednisone (Dehydrocortisone) is a synthetic glucocorticoid with anti-inflammatory and immunomodulating properties. |
| In vitro | Prednisone blocks Peripheral blood lymphocytes (PBL) growth in the G1 phase of cell cycle and inhibits both IL-2 receptor (IL-2R) expression and IL-2 secretion in activated human peripheral blood T lymphocytes. Prednisone increases apoptosis in PHA-activated human PBL, and the apoptotic effect of Prednisone is stronger on CD8(+) than on CD4(+) T lymphocytes. [1] |
| In vivo | Prednisone-treated rats show a significant delay of 20% in learning and memory retention in rats as compared with controls. [2] Prednisone results in reduced weight gain, unchanged alter uterine weight, lowered serum magnesium (Mg), unchange serum calcium (Ca), phosphate (P), 25-hydroxyvitamin D (25OHD), or 1,25-dihydroxyvitamin D [1,25(OH)2D], striking increased in calcified cartilage, reduced cross-sectional area and cortical area, unchange medullary area of the tibial diaphysis, lowered periosteal and endocortical bone formation and apposition rates, increased mean cancellous bone area and cancellous bone perimeter of the tibial metaphysis in both sham-operated and ovariectomized rats. [3] Prednisone-treated rabbit shows a 30% reduction in percent stenosis, a 35% decrease in neointimal area, and a 66% decrement in neointimal thickness. [4] Prednisone treatment significantly reduces the level of TGF-beta1 and HYP in diaphragm from mdx mice to values similar to control mice, but results in a higher level of the HP cross-link compared with untreated mdx mice. [5] |
| Synonyms | Dehydrocortisone |
| Molecular Weight | 358.43 |
| Formula | C21H26O5 |
| Cas No. | 53-03-2 |
| Smiles | 19[C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1(19)[C@@]2(19)CCC2=CC(=O)C=C[C@]12C |
| Relative Density. | 1.3g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | Ethanol: <1 mg/mL DMSO: 250 mg/mL (697.49 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.58 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
